Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2022 Update

John Vincent profile picture
John Vincent
21.92K Followers

Summary

  • Jeremy Grantham’s 13F portfolio value decreased from $20.73B to $18.46B this quarter.
  • GMO Capital increased Meta Platforms, Salesforce, Inc., Taiwan Semi, and Amazon.com while reducing UnitedHealth, Coca-Cola, Elevance Health, and Cisco Systems.
  • The largest three individual stock positions are Microsoft Corporation, Apple, & United Health and they add up to ~11% of the portfolio.

University Of Oxford And Its Smith School Of Enterprise And Environment Host ReSource 2012

Matthew Lloyd

This article is part of a series that provides an ongoing analysis of the changes made to GMO's 13F stock portfolio on a quarterly basis. It is based on GMO's regulatory 13F Form filed on 8/12/2022. Jeremy Grantham's 13F portfolio value decreased ~11% from $20.73B to $18.46B this quarter. The portfolio is diversified with recent 13F reports showing well over 500 different positions although most of them are very small. There are 45 securities that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. The largest five stakes are Microsoft Corporation, Apple, UnitedHealth, Alphabet, and US Bancorp. They add up to ~16% of the portfolio. Please visit our Tracking Jeremy Grantham's GMO Portfolio series to get an idea of their investment philosophy and our last report for the fund's moves during Q1 2022.

As of June 30, 2022, GMO's 7-year asset class real return forecast is for US Large Cap asset class to have a negative 1% annualized return on one end and Emerging Value asset class to have a positive 7.9% annualized return at the other extreme. Most of the bond category is also forecasted to have negative annualized real returns over the next 7 years. The firm currently has ~$65B under management, a far cry from ~$120B that they had at the peak. The assets are distributed among separately managed, institutional, and mutual fund accounts. Their flag ship mutual fund is GMO Benchmark-Free Allocation Fund (MUTF:GBMFX) which was incepted in 2003.

Note 1: It was reported in December 2020 that Jeremy Grantham has a ~4.8M share stake in QuantumScape (QS). The ~$12.5M investment was made 7 years ago as part of a series of bets on early-stage "green technology" companies.

Note 2: Jeremy Grantham has repeatedly said the US stock market is in a bubble since June 2020. The latest was a research note in early August to prepare for an "epic finale" to the deflating of the super bubble.

New Stakes:

Intuitive Surgical (ISRG): ISRG is a 0.66% of the portfolio position purchased this quarter at prices between ~$191 and ~$306. The stock currently trades at the bottom of that range at ~$191.

Stake Increases:

Microsoft Corporation (MSFT): MSFT is currently the top position in the portfolio at 4.44%. It is a very long-term stake. The 2007-2008 period saw the stake built from ~5.6M shares to over 59M shares at prices between $19 and $35. The position size peaked in 2011 at ~68M shares. The next four years saw the stake sold down by ~80% at prices between $28 and $56. Recent activity follows: the three years through Q3 2020 saw a ~70% selling at prices between ~$88 and ~$232. There was a ~9% trimming in Q4 2021 while this quarter there was a similar increase. The stock currently trades at ~$238.

Alphabet Inc. (GOOGL): GOOG is a top five 2.39% position. The long-term stake was built during the 2007-2014 timeframe at low prices. The position size peaked in 2014. Since then, the stake was reduced at prices between ~$25 and ~$150. The stock currently trades at ~$99. There was a marginal increase this quarter.

Meta Platforms (META), previously Facebook: META is a 1.41% of the portfolio position purchased in Q1 2018 at prices between ~$160 and ~$190. The stake had seen incremental buying since. Q4 2021 saw a ~11% trimming while last quarter there was a similar increase. There was a ~25% stake increase this quarter at prices between ~$156 and ~$234. The stock is now at ~$140.

Adobe (ADBE), AGCO Corp (AGCO), Ameresco (AMRC), Amazon.com (AMZN), BP plc (BP), Global Payments (GPN), KLA Corp. (KLAC), Sunrun Inc. (RUN), Salesforce, Inc. (CRM), Sociedad Quimica y Minera (SQM), SolarEdge Technologies (SEDG), Taiwan Semi (TSM), Teck Resources (TECK), and Visa Inc. (V): These small (less than ~1.5% of the portfolio each) stakes were increased this quarter.

Stake Decreases:

Apple Inc. (AAPL): AAPL is a top three 3.13% long-term stake. It was a large stake in 2005 but was sold down next year. The position was rebuilt in 2007 but was again sold down next year. Similar trading pattern continued over the next several years. The four years through 2019 saw a ~75% reduction at prices between ~$23 and ~$82. Q3 2020 saw another ~30% selling at prices between ~$91 and ~$134. The stock is now at ~$150. Last several quarters have seen only minor adjustments.

UnitedHealth Group (UNH): The top three ~3% of the portfolio stake in UNH was already a very large ~18M share position in 2005. The position size peaked in 2007 at over 20.5M shares. The five years through 2019 had seen a ~75% selling at prices between $102 and $296. That was followed with a ~25% reduction this quarter at prices between ~$452 and ~$546. The stock is now at ~$514.

U.S. Bancorp (USB): The 2.39% USB stake was purchased in 2017 at prices between $50 and $56 and the stock currently trades well below that range at $42.12. Q1 2020 saw a ~50% stake increase at prices between ~$29 and ~$55. Last several quarters have seen only minor adjustments.

Wells Fargo (WFC): The 2.19% WFC position was purchased in Q3 2017 at prices between $49.50 and $56. Q1 2020 saw a ~25% stake increase at prices between ~$25 and ~$49. That was followed with a ~30% stake increase in Q4 2020 at prices between ~$21 and ~$30. There was a ~18% selling over the next two quarters at prices between ~$30 and ~$48. The stock is now at $40.41. Last few quarters have seen only minor adjustments.

Johnson & Johnson (JNJ): JNJ is a very long-term stake. In their first 13F filing in 2005, the position was at ~170K shares. The sizing peaked at around 26M shares in 2009. The stake was sold down by ~40% in 2014 at prices between $88 and $109. 2016 saw another ~50% selling at prices between $97 and $125. The ten quarters through Q2 2019 also saw minor selling almost every quarter. The pattern reversed in Q3 2019: 23% stake increase in H2 2019 at prices between $127 and $146. H1 2020 saw a ~15% trimming and that was followed with a ~12% reduction this quarter. The stock currently trades at ~$167 and the stake is at 2.19% of the portfolio.

Coca-Cola (KO): KO is a ~2% of the portfolio stake. The position was already a large 7M share stake in 2005. That original stake was built to 23.7M shares during the 2007-2008 timeframe at price between $20 and $32. The sizing peaked at almost 39M shares in 2012. The next five years saw the position sold down by ~90% to a ~3.7M share stake at prices between $37 and $47. Recent activity follows. Q1 2020 saw a ~75% stake increase at prices between $37.50 and $60. That was followed with a ~37% increase in Q3 2020 at prices between ~$44 and ~$51. This quarter saw a similar reduction at prices between ~$59 and ~$66. The stock is now at $58.60.

Accenture plc (ACN): ACN became a significant part of the portfolio during the 2013-2014 timeframe when around 3.8M shares were purchased at prices between $69 and $85. The next five years had seen a combined ~50% reduction through minor selling most quarters. The two quarters through Q3 2021 saw another ~24% reduction at prices between ~$295 and ~$415. The stock currently trades at ~$260 and the stake is at ~2% of the portfolio. Last three quarters have seen only minor adjustments.

Texas Instruments (TXN): TXN is a 1.95% of the portfolio position. The majority of the stake was purchased in Q3 & Q4 2016 at prices between $63 and $75. There was a ~20% stake increase last quarter at prices between ~$163 and ~$191. The stock currently trades at ~$161. There was a minor ~2% trimming this quarter.

Elevance Health (ELV): ELV position was first purchased in 2014. The bulk of the current 1.91% portfolio stake was established in 2017 at prices between $144 and $232. There was a roughly one-third selling over the last two quarters at prices between ~$428 and ~$530. The stock currently trades at ~$454.

Oracle Corporation (ORCL): The 1.78% ORCL position is a very long-term stake. The position was already at around 14M shares in 2007. The next two years saw the stake built to a much larger 62M share position at prices between $15.50 and $24.50. Next few years saw selling at higher prices and by 2017 the stake was back at 14M shares. The five quarters through Q2 2019 saw another ~45% selling at prices between $44 and $57. Q1 2020 also saw a ~18% reduction at prices between ~$40 and ~$56. Last three quarters saw another ~30% selling at prices between ~$64 and ~$104. The stock is currently at $64.55.

Lam Research (LRCX): The 1.74% LRCX stake was built in Q3 2020 at prices between ~$294 and ~$385 and the stock is now at ~$381. This quarter saw marginal trimming.

Merck & Co. (MRK): MRK is a very long-term stake. In 2014, it was sold down to a very small position at prices between $50 and $62. The stake was rebuilt in H1 2018 at prices between $53 and $63. Q1 2020 saw a ~20% selling at prices between ~$66 and ~$92. Last seven quarters had seen a ~30% stake increase at prices between ~$69 and ~$88. There was a ~20% reduction this quarter at prices between ~$84 and ~$95. The stock currently trades at $86.78, and the stake is at 1.54% of the portfolio.

TJX Companies (TJX): TJX is a 1.46% of the portfolio position that has been in the portfolio for well over fifteen years. The position has wavered. Last major activity was a ~25% stake increase in H1 2020 at prices between ~$37 and ~$63. The stock is now at $61.27. Last several quarters had seen minor increases while this quarter saw a ~6% trimming.

American Express (AXP), Abbott Labs (ABT), Cisco Systems (CSCO), Cigna (CI), Canadian Solar (CSIQ), Clean Energy Fuels (CLNE), Constellation Brands (STZ), Darling Ingredients (DAR), Eli Lilly (LLY), Kosmos Energy (KOS), Lyft, Inc. (LYFT), Medtronic plc (MDT), Otis Worldwide (OTIS), and Quest Diagnostics (DGX): These very small (less than ~1.5% of the portfolio each) positions were reduced this quarter.

Note: Although the position sizes relative to the overall portfolio is very small, it is significant that GMO has sizable ownership stakes in the following businesses: Clean Energy Fuels, Canadian Solar, and Kosmos Energy.

Below is a spreadsheet that shows the changes to Jeremy Grantham's GMO Capital 13F portfolio holdings as of Q2 2022:

Jeremy Grantham - GMO Capital's Q2 2022 13F Report Q/Q Comparison

Jeremy Grantham - GMO Capital's Q2 2022 13F Report Q/Q Comparison (John Vincent (author))

This article was written by

John Vincent profile picture
21.92K Followers
Focused on cloning strategies by analyzing 13F reports of a curated set of around fifty super-investors and generating Absolute Returns thru exploiting inefficiency, volatility, and momentum.

Disclosure: I/we have a beneficial long position in the shares of AAPL, AMZN, GOOGL, META either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (10)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.